Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs

Overview

Journal Pharmacy (Basel)

Date 2018 Jan 25

PMID 29361723

Citations 29

Authors

Donatella Zodda

Rosario Giammona

Silvia Schifilliti

Affiliations

Soon will be listed here.

Abstract

Prevention and treatment of dyslipidemia should be considered as an integral part of individual cardiovascular prevention interventions, which should be addressed primarily to those at higher risk who benefit most. To date, statins remain the first-choice therapy, as they have been shown to reduce the risk of major vascular events by lowering low-density lipoprotein cholesterol (LDL-C). However, due to adherence to statin therapy or statin resistance, many patients do not reach LDL-C target levels. Ezetimibe, fibrates, and nicotinic acid represent the second-choice drugs to be used in combination with statins if lipid targets cannot be reached. In addition, anti-PCSK9 drugs (evolocumab and alirocumab) provide an effective solution for patients with familial hypercholesterolemia (FH) and statin intolerance at very high cardiovascular risk. Recently, studies demonstrated the effects of two novel lipid-lowering agents (lomitapide and mipomersen) for the management of homozygous FH by decreasing LDL-C values and reducing cardiovascular events. However, the costs for these new therapies made the cost-effectiveness debate more complicated.

Citing Articles

Lipids dysregulation in diseases: core concepts, targets and treatment strategies.

Dakal T, Xiao F, Bhusal C, Sabapathy P, Segal R, Chen J Lipids Health Dis. 2025; 24(1):61.

PMID: 39984909 PMC: 11843775. DOI: 10.1186/s12944-024-02425-1.

Protective Role of Methanol Leaf Extract of Catharanthus Roseus in Lipid Profile Modulation in Diabetic Wistar Rats.

Mallikarjuna Rao B, Vedavijaya T, Ramani Y, Sayana S Cureus. 2025; 17(1):e77420.

PMID: 39949440 PMC: 11823276. DOI: 10.7759/cureus.77420.

Phytochemicals and Functional Properties of Pitaya Juice Powders.

Herrera M, Zegbe J, Reveles-Torres L Plants (Basel). 2024; 13(21).

PMID: 39519958 PMC: 11548265. DOI: 10.3390/plants13213040.

Antisense Oligonucleotides in Dyslipidemia Management: A Review of Clinical Trials.

Ogieuhi I, Callender K, Odukudu G, Obi E, Muzofa K, Babalola A High Blood Press Cardiovasc Prev. 2024; 32(1):33-47.

PMID: 39476283 DOI: 10.1007/s40292-024-00682-w.

Two Triterpenoids, ARM-2 and RA-5, From Exhibit the Potential to Modulate Lipolysis and Lipogenesis in Cultured 3T3-L1 Adipocytes.

Ndlovu M, Serem J, Bester M, Apostolides Z, Opoku A, Mosa R J Lipids. 2024; 2024:3972941.

PMID: 39450349 PMC: 11502128. DOI: 10.1155/2024/3972941.

References

Kazi D, Moran A, Coxson P, Penko J, Ollendorf D, Pearson S . Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. JAMA. 2016; 316(7):743-53. DOI: 10.1001/jama.2016.11004. View

Miller D, Spence J . Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998; 34(2):155-62. DOI: 10.2165/00003088-199834020-00003. View

Dixon D, Sisson E, Butler M, Higbea A, Muoio B, Turner B . Lomitapide and mipomersen: novel lipid-lowering agents for the management of familial hypercholesterolemia. J Cardiovasc Nurs. 2013; 29(5):E7-E12. DOI: 10.1097/JCN.0000000000000104. View

Cuchel M, Meagher E, du Toit Theron H, Blom D, Marais A, Hegele R . Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2012; 381(9860):40-6. PMC: 4587657. DOI: 10.1016/S0140-6736(12)61731-0. View

Toth P, Worthy G, Gandra S, Sattar N, Bray S, Cheng L . Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia. J Am Heart Assoc. 2017; 6(10). PMC: 5721820. DOI: 10.1161/JAHA.116.005367. View

Tenenbaum A, Motro M, Fisman E, Tanne D, Boyko V, Behar S . Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med. 2005; 165(10):1154-60. DOI: 10.1001/archinte.165.10.1154. View

Fulcher J, OConnell R, Voysey M, Emberson J, Blackwell L, Mihaylova B . Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015; 385(9976):1397-405. DOI: 10.1016/S0140-6736(14)61368-4. View

Sasaki J, Yamamoto K, Ageta M . Effects of fenofibrate on high-density lipoprotein particle size in patients with hyperlipidemia: a randomized, double-blind, placebo-controlled, multicenter, crossover study. Clin Ther. 2002; 24(10):1614-26. DOI: 10.1016/s0149-2918(02)80064-9. View

Reiner Z, De Bacquer D, Kotseva K, Prugger C, De Backer G, Wood D . Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: findings from the EUROASPIRE III survey. Atherosclerosis. 2013; 231(2):300-7. DOI: 10.1016/j.atherosclerosis.2013.09.020. View

10.

Reiner Z, Catapano A, De Backer G, Graham I, Taskinen M, Wiklund O . ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011; 32(14):1769-818. DOI: 10.1093/eurheartj/ehr158. View

11.

Cornier M, Eckel R . Non-traditional dosing of statins in statin-intolerant patients-is it worth a try?. Curr Atheroscler Rep. 2014; 17(2):475. DOI: 10.1007/s11883-014-0475-4. View

12.

Schulz I . [Treatment of dyslipidemia: how and when to combine lipid lowering drugs]. Arq Bras Endocrinol Metabol. 2006; 50(2):344-59. DOI: 10.1590/s0004-27302006000200021. View

13.

Kornitzer M, Dramaix M, Vandenbroek M, Everaert L, Gerlinger C . Efficacy and tolerance of 200 mg micronised fenofibrate administered over a 6-month period in hyperlipidaemic patients: an open Belgian multicenter study. Atherosclerosis. 1994; 110 Suppl:S49-54. DOI: 10.1016/0021-9150(94)05378-v. View

14.

Bove M, Fogacci F, Cicero A . Pharmacokinetic drug evaluation of ezetimibe + simvastatin for the treatment of hypercholesterolemia. Expert Opin Drug Metab Toxicol. 2017; 13(10):1099-1104. DOI: 10.1080/17425255.2017.1381085. View

15.

Maxfield F, van Meer G . Cholesterol, the central lipid of mammalian cells. Curr Opin Cell Biol. 2010; 22(4):422-9. PMC: 2910236. DOI: 10.1016/j.ceb.2010.05.004. View

16.

Ricotta D, Frishman W . Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia. Cardiol Rev. 2012; 20(2):90-5. DOI: 10.1097/CRD.0b013e31823424be. View

17.

Jakob T, Nordmann A, Schandelmaier S, Ferreira-Gonzalez I, Briel M . Fibrates for primary prevention of cardiovascular disease events. Cochrane Database Syst Rev. 2016; 11:CD009753. PMC: 6464497. DOI: 10.1002/14651858.CD009753.pub2. View

18.

Davidson M . A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia. J Clin Lipidol. 2011; 5(2):76-81. DOI: 10.1016/j.jacl.2011.01.005. View

19.

Davis K, Miyares M . Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia. Am J Health Syst Pharm. 2014; 71(12):1001-8. DOI: 10.2146/ajhp130592. View

20.

Polychronopoulos G, Tziomalos K . Novel treatment options for the management of heterozygous familial hypercholesterolemia. Expert Rev Clin Pharmacol. 2017; 10(12):1375-1381. DOI: 10.1080/17512433.2017.1378096. View